Eculizumab Salvage Therapy for Antibody-Mediated Rejection in a Desensitization-Resistant Intestinal Re-Transplant Patient

American Journal of Transplantation

Volumn 15, Issue 7, 2015, Pages 1995-2000

  Fan, J ^a   Tryphonopoulos, P ^a   Tekin, A ^a   Nishida, S ^a   Selvaggi, G ^a   Amador, A ^a   Jebrock, J ^a   Weppler, D ^c   Levi, D ^b   Vianna, R ^a   Ruiz, P ^a   Tzakis, A ^c  

^a UNIVERSITY OF MIAMI   (United States)

^b CAROLINAS MEDICAL CENTER   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BORTEZOMIB; CEFTRIAXONE; COMPLEMENT COMPONENT C4D; ECULIZUMAB; GANCICLOVIR; IMMUNOGLOBULIN; LEVOFLOXACIN; MENINGOCOCCUS VACCINE; PANEL REACTIVE ANTIBODY; RITUXIMAB; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; ALLOANTIBODY; MONOCLONAL ANTIBODY;

ACUTE ANTIBODY MEDIATED REJECTION; ACUTE GRAFT REJECTION; ADOLESCENT; ANTIBODY MEDIATED REJECTION; ARTICLE; ARTIFICIAL EMBOLISM; BLUNT TRAUMA; CASE REPORT; CHRONIC GRAFT REJECTION; DESENSITIZATION; DISEASE DURATION; DISEASE SEVERITY; DRUG DOSE REDUCTION; FEVER; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; GRANULATION TISSUE; HUMAN; HYPOTENSION; ILEUM GRAFT; IMMUNOSUPPRESSIVE TREATMENT; INTESTINE GRAFT; INTESTINE TRANSPLANTATION; MALE; MENINGOCOCCOSIS; METABOLIC ACIDOSIS; MONOTHERAPY; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PLASMAPHERESIS; PRIORITY JOURNAL; RETRANSPLANTATION; SALVAGE THERAPY; SCAR; SHORT BOWEL SYNDROME; SMALL INTESTINE OBSTRUCTION; SUPERIOR MESENTERIC ARTERY; TOTAL PARENTERAL NUTRITION; TREATMENT DURATION; COMPLICATION; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOLOGY; INTESTINAL DISEASES; INTESTINE; PATHOLOGY; POSTOPERATIVE COMPLICATION; PROGNOSIS; REOPERATION; TRANSPLANTATION;

ADOLESCENT; ANTIBODIES, MONOCLONAL, HUMANIZED; DESENSITIZATION, IMMUNOLOGIC; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; INTESTINAL DISEASES; INTESTINES; ISOANTIBODIES; MALE; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; REOPERATION; SALVAGE THERAPY;

EID: 84931571808     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.13183     Document Type: Article

References (18)

1. Gonzalez-Pinto IM, Tzakis AG, Tsai HL, et al., Association between panel reactive antibodies and acute small bowel rejection: Analysis of a series of 324 intestinal transplants. Transplant Proc 2010; 42: 4269-4271.
2. Tsai HL, Island ER, Chang JW, et al., Association between donor-specific antibodies and acute rejection and resolution in small bowel and multivisceral transplantation. Transplantation 2011; 92: 709-715.
3. Gondolesi G, Blondeau B, Maurette R, et al., Pretransplant immunomodulation of highly sensitized small bowel transplant candidates with intravenous immune globulin. Transplantation 2006; 81: 1743-1746.
4. Vianna RM, Mangus RS, Fridell JA, Weigman S, Kazimi M, Tector J,. Induction immunosuppression with thymoglobulin and rituximab in intestinal and multivisceral transplantation. Transplantation 2008; 85: 1290-1293.
5. Gerlach UA, Schoenemann C, Lachmann N, Koch M, Pascher A,. Salvage therapy for refractory rejection and persistence of donor-specific antibodies after intestinal transplantation using the proteasome inhibitor bortezomib. Transpl Int 2011; 24: e43-e45.
6. Island ER, Gonzalez-Pinto IM, Tsai HL, et al., Successful treatment with bortezomib of a refractory humoral rejection of the intestine after multivisceral transplantation. Clin Transpl 2009; 465-469.
7. Stegall MD, Diwan T, Raghavaiah S, et al., Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant 2011; 11: 2405-2413.
8. Kocak B, Arpali E, Demiralp E, et al., Eculizumab for salvage treatment of refractory antibody-mediated rejection in kidney transplant patients: Case reports. Transplant Proc 2013; 45: 1022-1025.
9. Corcos O, Cazals-Hatem D, Hertig A, et al., Treatment of refractory anti-HLA antibody-mediated rejection with eculizumab in an adult with combined liver and small bowel transplantation. Transplantation 2012; 94: 735.
10. Levi DM, Tzakis AG, Kato T, et al., Transplantation of the abdominal wall. Lancet 2003; 361: 2173-2176.
11. Ruiz P, Bagni A, Brown R, et al., Histological criteria for the identification of acute cellular rejection in human small bowel allografts: Results of the pathology workshop at the VIII International Small Bowel Transplant Symposium. Transplant Proc 2004; 36: 335-337.
12. Fan J, Tekin A, Nishida S, et al., Preoperative embolization of the graft superior mesenteric artery assists graft enterectomy in intestinal transplant recipients. Transplantation 2012; 94: 89-91.
13. Woodle ES, Walsh RC, Alloway RR, Girnita A, Brailey P., Proteasome inhibitor therapy for antibody-mediated rejection. Pediatr Transplant 2011; 15: 548-556.
14. Kim M, Martin ST, Townsend KR, Gabardi S., Antibody-mediated rejection in kidney transplantation: A review of pathophysiology, diagnosis, and treatment options. Pharmacotherapy 2014; 34: 733-744.
15. Stegall MD, Chedid MF, Cornell LD., The role of complement in antibody-mediated rejection in kidney transplantation. Nat Rev Nephrol 2012; 8: 670-678.
16. Bouts A, Monnens L, Davin JC, Struijk G, Spanjaard L., Insufficient protection by Neisseria meningitidis vaccination alone during eculizumab therapy. Pediatr Nephrol 2011; 26: 1919-1920.
17. Abu-Elmagd KM, Wu G, Costa G, et al., Preformed and de novo donor specific antibodies in visceral transplantation: Long-term outcome with special reference to the liver. Am J Transplant 2012; 12: 3047-3060.
18. Desai CS, Khan KM, Gruessner AC, Fishbein TM, Gruessner RW., Intestinal retransplantation: Analysis of Organ Procurement and Transplantation Network database. Transplantation 2012; 93: 120-125.